Disruption of memory B-cell trafficking by belimumab in patients with systemic lupus erythematosus.

Autor: Arends EJ; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands., Zlei M; Department of Immunology, Leiden University Medical Centre, Leiden, The Netherlands.; Medical Laboratory, Department of Flow Cytometry, Regional Institute of Oncology, Iasi, Romania., Tipton CM; Lowance Centre for Human Immunology, Emory University School of Medicine, Atlanta, GA, USA.; Department of Medicine, Division of Rheumatology, Emory University, Atlanta, GA, USA., Cotic J; Clinical Statistics, GSK, Middlesex, UK., Osmani Z; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands., de Bie FJ; Department of Immunology, Leiden University Medical Centre, Leiden, The Netherlands., Kamerling SWA; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands., van Maurik A; Clinical Pharmacology and Experimental Medicine, GSK, Hertfordshire, UK., Dimelow R; Clinical Pharmacology Modelling and Simulation, GSK, Hertfordshire, UK., Gregan YI; Clinical Science Immunology, GSK, Collegeville, PA, USA., Fox NL; Clinical Development, GSK, Collegeville, PA, USA., Rabelink TJ; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands., Roth DA; Research and Development, GSK, Collegeville, PA, USA., Sanz I; Lowance Centre for Human Immunology, Emory University School of Medicine, Atlanta, GA, USA., van Dongen JJM; Centro de Investigación del Cáncer-Instituto de Biología Molecular y Celular del Cáncer (CIC-IBMCC, USAL-CSIC-FICUS) and Department of Medicine, University of Salamanca, Salamanca, Spain., van Kooten C; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands., Teng YKO; Expert Center for Lupus-, Vasculitis-, and Complement-Mediated Systemic diseases (LuVaCs), Department of Internal Medicine-Section Nephrology, Leiden University Medical Centre, Leiden, The Netherlands.

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2024 Sep 01; Vol. 63 (9), pp. 2387-2398.

Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.

Autor: van Schaik M; Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Internal Medicine - Section Nephrology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands., Arends EJ; Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Internal Medicine - Section Nephrology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands., Soonawala D; Department of Nephrology, HagaZiekenhuis, Els Borst-Eilersplein 275, 2545 AA, The Hague, the Netherlands., van Ommen E; Department of Nephrology, Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA, Nijmegen, the Netherlands., de Leeuw K; Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Hanzeplein 1, 9713 GZ, Groningen, the Netherlands., Limper M; Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands., van Paassen P; Department of Nephrology and Clinical Immunology, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX, Maastricht, the Netherlands., Huizinga TWJ; Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands., Toes REM; Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands., van Kooten C; Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Internal Medicine - Section Nephrology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands., Rotmans JI; Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Internal Medicine - Section Nephrology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands., Rabelink TJ; Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Internal Medicine - Section Nephrology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands., Teng YKO; Center of Expertise for Lupus, Vasculitis and Complement-mediated Systemic disease (LuVaCs), Department of Internal Medicine - Section Nephrology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, the Netherlands. Y.K.O.Teng@lumc.nl.; Department of Nephrology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, the Netherlands. Y.K.O.Teng@lumc.nl.

Publikováno v: Trials [Trials] 2022 Nov 12; Vol. 23 (1), pp. 939. Date of Electronic Publication: 2022 Nov 12.

Increased Tacrolimus Exposure in Kidney Transplant Recipients With COVID-19: Inflammation-Driven Downregulation of Metabolism as a Potential Mechanism.

Autor: Klomp SD; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands.; Leiden Network for Personalised Therapeutics, Leiden University Medical Center, Leiden, Netherlands., Meziyerh S; Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, Netherlands.; Leiden Transplant Center, Leiden University Medical Center, Leiden, Netherlands., Vissers MFJM; Centre for Human Drug Research, Leiden, Netherlands.; Leiden University Medical Center, Leiden, Netherlands., Moes DJAR; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands., Arends EJ; Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, Netherlands.; Leiden Transplant Center, Leiden University Medical Center, Leiden, Netherlands., Teng YKO; Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, Netherlands.; Leiden Transplant Center, Leiden University Medical Center, Leiden, Netherlands., Swen JJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Netherlands.; Leiden Network for Personalised Therapeutics, Leiden University Medical Center, Leiden, Netherlands., de Vries APJ; Department of Internal Medicine, Division of Nephrology, Leiden University Medical Center, Leiden, Netherlands.; Leiden Transplant Center, Leiden University Medical Center, Leiden, Netherlands.

Publikováno v: Transplant international : official journal of the European Society for Organ Transplantation [Transpl Int] 2022 May 16; Vol. 35, pp. 10269. Date of Electronic Publication: 2022 May 16 (Print Publication: 2022).

Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients.

Autor: van Dam LS; Centre of Expertise for Lupus-, Vasculitis-, and Complement-Mediated Systemic Autoimmune Diseases (LuVaCs), Department of Internal Medicine, section Nephrology, Leiden University Medical Center, Leiden, Netherlands., Oskam JM; Centre of Expertise for Lupus-, Vasculitis-, and Complement-Mediated Systemic Autoimmune Diseases (LuVaCs), Department of Internal Medicine, section Nephrology, Leiden University Medical Center, Leiden, Netherlands., Kamerling SWA; Centre of Expertise for Lupus-, Vasculitis-, and Complement-Mediated Systemic Autoimmune Diseases (LuVaCs), Department of Internal Medicine, section Nephrology, Leiden University Medical Center, Leiden, Netherlands., Arends EJ; Centre of Expertise for Lupus-, Vasculitis-, and Complement-Mediated Systemic Autoimmune Diseases (LuVaCs), Department of Internal Medicine, section Nephrology, Leiden University Medical Center, Leiden, Netherlands., Bredewold OW; Centre of Expertise for Lupus-, Vasculitis-, and Complement-Mediated Systemic Autoimmune Diseases (LuVaCs), Department of Internal Medicine, section Nephrology, Leiden University Medical Center, Leiden, Netherlands., Berkowska MA; Immunomonitoring group, Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, Netherlands., van Dongen JJM; Immunomonitoring group, Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, Netherlands., Rabelink TJ; Centre of Expertise for Lupus-, Vasculitis-, and Complement-Mediated Systemic Autoimmune Diseases (LuVaCs), Department of Internal Medicine, section Nephrology, Leiden University Medical Center, Leiden, Netherlands., van Kooten C; Centre of Expertise for Lupus-, Vasculitis-, and Complement-Mediated Systemic Autoimmune Diseases (LuVaCs), Department of Internal Medicine, section Nephrology, Leiden University Medical Center, Leiden, Netherlands., Teng YKO; Centre of Expertise for Lupus-, Vasculitis-, and Complement-Mediated Systemic Autoimmune Diseases (LuVaCs), Department of Internal Medicine, section Nephrology, Leiden University Medical Center, Leiden, Netherlands.

Publikováno v: Frontiers in immunology [Front Immunol] 2020 Dec 15; Vol. 11, pp. 566732. Date of Electronic Publication: 2020 Dec 15 (Print Publication: 2020).